Year-end Sale % OFF 
Abstract
Tuberculosis (TB) has huge impact on human morbidity and mortality and biomarkers to support rapid TB diagnosis and ensure treatment initiation and cure are needed, especially in regions with high prevalence of multi-drug resistant TB. Soluble interferon gamma inducible protein 10 (IP-10) analyzed from dry plasma spots (DPS) has potential as an immunodiagnostic marker in TB infection. We analyzed IP-10 levels in plasma directly and extracted from DPS in parallel by ELISA from 34 clinically well characterized patients with TB disease before and throughout 24 weeks of effective anti-TB chemotherapy. We detected a significant decline of IP-10 levels in both plasma and DPS already after two weeks of therapy with good correlation between the tests. This was observed both in pulmonary and extrapulmonary TB. In conclusion, plasma IP-10 may serve as an early biomarker for anti-TB chemotherapy responses and the IP-10 DPS method has potential to be developed into a point-of care test for use in resource-limited settings. Further studies must be performed to validate the use of IP-10 DPS in TB high endemic countries.
Highlights
Correspondence and requests for materials should be addressed to inducible protein 10 (IP-10) measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection
Plasma IP-10 may serve as an early biomarker for anti-TB chemotherapy responses and the IP-10 dry plasma spots (DPS) method has potential to be developed into a point-of care test for use in resource-limited settings
We report for the first time that plasma IP-10, as measured by both methods, declined in response to anti-TB chemotherapy
Summary
Correspondence and requests for materials should be addressed to IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection. The diagnostic accuracy of IP-10 for TB infection seems to be on par with interferon gamma (IFN-c)-release assays (IGRAs), but plasma IP-10 is expressed at a much higher level than IFN-c and considered a more robust marker[8] Data from both animal[9,10] and human studies[11,12,13,14,15,16,17] suggest that plasma IP-10 has potential as a biomarker for therapy responses in TB. Our data indicate that the IP-10 DPS assay has potential as a biomarker for treatment responses and TB cure and may be developed into use as a POC test in resource-limited settings
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
